2025 Q4 -tulosraportti
Vain PDF
32 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·55 min sittenNo form of buy recommendation or attempt at hyping. Article from NRK about research on CAR-T in the treatment of diseases. Circio not mentioned, but interesting article within the field. Please correct if it's a misstep to post. https://www.nrk.no/norge/nytt-hap-for-behandling-av-autoimmunsykdom_-_-kan-blir-et-stort-gjennombrudd-1.17869620
·3 t sittenDAGSREVYEN SHOWS THE FUTURE: THE ENORMOUS SHIFT IN AUTOIMMUNE DISEASES 🧬📺 When Dagsrevyen uses prime time on National Day to talk about the massive shift in autoimmune diseases, everyone who understands biotech should open their eyes wide. Mainstream media is finally starting to wake up. What is happening in medicine right now is a paradigm shift: Advanced cell therapy (like CAR-T) is no longer just a "cancer thing". It is moving at rocket speed into autoimmune diseases – a market that is unfathomably large. In autoimmune diseases, the immune system has gone on autopilot and attacks the body's own cells. The solution? Reprogram the immune cells to behave properly. But today's cell therapy has a gigantic problem: Logistics. • Take cells out of the patient. • Modify them in a lab. • Grow them. • Put them back. This is extremely expensive, slow, and impossible to scale to millions of patients. This is where the holy grail comes in: In vivo cell therapy. Don't take the cells out of the body. Program them directly inside. Turn cell therapy into an off-the-shelf product. To achieve that, you need two things: An extremely precise delivery method (targeted LNP), and a stable engine that lasts long enough in the cell to do the job (circRNA). This is exactly what is at the core of the Acuitas collaboration and the T-cell track for which we are now awaiting data in Q2. When you combine the world's most advanced LNP technology with a circular RNA engine that does not break down immediately, you have the recipe for solving gene therapy's biggest bottleneck. Dagsrevyen shows us where the market is going. The data in the coming weeks will show who has the tools to take us there. Cancer was just chapter one. Autoimmune diseases are the next gigantic chapter – and in vivo programming is the key. We know what we own. 🧬♟️🧱🍷
·3 t sittenWhat they showed here was not in-vivo and already obsolete, as we Circio shareholders know. Maybe we should have tipped dagsrevyen that they are serving old news.
·2 t sittenThe only thing that matters to me is that the stock price rises, in a little over 12 hours we will get an answer as to whether that happens tomorrow or not....
·5 t sitten · MuokattuREGENXBIO fell sharply on the stock market the other day, after mixed results for their Duchenne gene therapy RGX-202. The treatment showed promising efficacy in many patients, but two serious side effects (liver damage and myocarditis) raised concerns about safety and FDA approval. It's exciting what a validated circVec platform could have achieved with lower doses, potentially reducing the immune response and liver burden that many AAV therapies struggle with today. Circio/circVec could practically become an important key to the next generation of Duchenne treatments. https://www.biospace.com/drug-development/regenxbio-slumps-after-serious-side-effects-mar-Duchenne-gene%20therapy-results Bonusinfo: Duchenne Muscular Dystrophy is a serious hereditary muscle disease where the body lacks the protein dystrophin, which is necessary to protect the muscles. The disease primarily affects boys and gradually leads to weaker muscles, problems with walking, cardiac and pulmonary involvement, and shortened lifespan. The most advanced treatments are gene therapy and exon-skipping, where one attempts either to repair genetic defects or help the body produce a shortened version of dystrophin.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
32 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·55 min sittenNo form of buy recommendation or attempt at hyping. Article from NRK about research on CAR-T in the treatment of diseases. Circio not mentioned, but interesting article within the field. Please correct if it's a misstep to post. https://www.nrk.no/norge/nytt-hap-for-behandling-av-autoimmunsykdom_-_-kan-blir-et-stort-gjennombrudd-1.17869620
- ·3 t sittenDAGSREVYEN SHOWS THE FUTURE: THE ENORMOUS SHIFT IN AUTOIMMUNE DISEASES 🧬📺 When Dagsrevyen uses prime time on National Day to talk about the massive shift in autoimmune diseases, everyone who understands biotech should open their eyes wide. Mainstream media is finally starting to wake up. What is happening in medicine right now is a paradigm shift: Advanced cell therapy (like CAR-T) is no longer just a "cancer thing". It is moving at rocket speed into autoimmune diseases – a market that is unfathomably large. In autoimmune diseases, the immune system has gone on autopilot and attacks the body's own cells. The solution? Reprogram the immune cells to behave properly. But today's cell therapy has a gigantic problem: Logistics. • Take cells out of the patient. • Modify them in a lab. • Grow them. • Put them back. This is extremely expensive, slow, and impossible to scale to millions of patients. This is where the holy grail comes in: In vivo cell therapy. Don't take the cells out of the body. Program them directly inside. Turn cell therapy into an off-the-shelf product. To achieve that, you need two things: An extremely precise delivery method (targeted LNP), and a stable engine that lasts long enough in the cell to do the job (circRNA). This is exactly what is at the core of the Acuitas collaboration and the T-cell track for which we are now awaiting data in Q2. When you combine the world's most advanced LNP technology with a circular RNA engine that does not break down immediately, you have the recipe for solving gene therapy's biggest bottleneck. Dagsrevyen shows us where the market is going. The data in the coming weeks will show who has the tools to take us there. Cancer was just chapter one. Autoimmune diseases are the next gigantic chapter – and in vivo programming is the key. We know what we own. 🧬♟️🧱🍷·3 t sittenWhat they showed here was not in-vivo and already obsolete, as we Circio shareholders know. Maybe we should have tipped dagsrevyen that they are serving old news.·2 t sittenThe only thing that matters to me is that the stock price rises, in a little over 12 hours we will get an answer as to whether that happens tomorrow or not....
- ·5 t sitten · MuokattuREGENXBIO fell sharply on the stock market the other day, after mixed results for their Duchenne gene therapy RGX-202. The treatment showed promising efficacy in many patients, but two serious side effects (liver damage and myocarditis) raised concerns about safety and FDA approval. It's exciting what a validated circVec platform could have achieved with lower doses, potentially reducing the immune response and liver burden that many AAV therapies struggle with today. Circio/circVec could practically become an important key to the next generation of Duchenne treatments. https://www.biospace.com/drug-development/regenxbio-slumps-after-serious-side-effects-mar-Duchenne-gene%20therapy-results Bonusinfo: Duchenne Muscular Dystrophy is a serious hereditary muscle disease where the body lacks the protein dystrophin, which is necessary to protect the muscles. The disease primarily affects boys and gradually leads to weaker muscles, problems with walking, cardiac and pulmonary involvement, and shortened lifespan. The most advanced treatments are gene therapy and exon-skipping, where one attempts either to repair genetic defects or help the body produce a shortened version of dystrophin.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
32 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·55 min sittenNo form of buy recommendation or attempt at hyping. Article from NRK about research on CAR-T in the treatment of diseases. Circio not mentioned, but interesting article within the field. Please correct if it's a misstep to post. https://www.nrk.no/norge/nytt-hap-for-behandling-av-autoimmunsykdom_-_-kan-blir-et-stort-gjennombrudd-1.17869620
- ·3 t sittenDAGSREVYEN SHOWS THE FUTURE: THE ENORMOUS SHIFT IN AUTOIMMUNE DISEASES 🧬📺 When Dagsrevyen uses prime time on National Day to talk about the massive shift in autoimmune diseases, everyone who understands biotech should open their eyes wide. Mainstream media is finally starting to wake up. What is happening in medicine right now is a paradigm shift: Advanced cell therapy (like CAR-T) is no longer just a "cancer thing". It is moving at rocket speed into autoimmune diseases – a market that is unfathomably large. In autoimmune diseases, the immune system has gone on autopilot and attacks the body's own cells. The solution? Reprogram the immune cells to behave properly. But today's cell therapy has a gigantic problem: Logistics. • Take cells out of the patient. • Modify them in a lab. • Grow them. • Put them back. This is extremely expensive, slow, and impossible to scale to millions of patients. This is where the holy grail comes in: In vivo cell therapy. Don't take the cells out of the body. Program them directly inside. Turn cell therapy into an off-the-shelf product. To achieve that, you need two things: An extremely precise delivery method (targeted LNP), and a stable engine that lasts long enough in the cell to do the job (circRNA). This is exactly what is at the core of the Acuitas collaboration and the T-cell track for which we are now awaiting data in Q2. When you combine the world's most advanced LNP technology with a circular RNA engine that does not break down immediately, you have the recipe for solving gene therapy's biggest bottleneck. Dagsrevyen shows us where the market is going. The data in the coming weeks will show who has the tools to take us there. Cancer was just chapter one. Autoimmune diseases are the next gigantic chapter – and in vivo programming is the key. We know what we own. 🧬♟️🧱🍷·3 t sittenWhat they showed here was not in-vivo and already obsolete, as we Circio shareholders know. Maybe we should have tipped dagsrevyen that they are serving old news.·2 t sittenThe only thing that matters to me is that the stock price rises, in a little over 12 hours we will get an answer as to whether that happens tomorrow or not....
- ·5 t sitten · MuokattuREGENXBIO fell sharply on the stock market the other day, after mixed results for their Duchenne gene therapy RGX-202. The treatment showed promising efficacy in many patients, but two serious side effects (liver damage and myocarditis) raised concerns about safety and FDA approval. It's exciting what a validated circVec platform could have achieved with lower doses, potentially reducing the immune response and liver burden that many AAV therapies struggle with today. Circio/circVec could practically become an important key to the next generation of Duchenne treatments. https://www.biospace.com/drug-development/regenxbio-slumps-after-serious-side-effects-mar-Duchenne-gene%20therapy-results Bonusinfo: Duchenne Muscular Dystrophy is a serious hereditary muscle disease where the body lacks the protein dystrophin, which is necessary to protect the muscles. The disease primarily affects boys and gradually leads to weaker muscles, problems with walking, cardiac and pulmonary involvement, and shortened lifespan. The most advanced treatments are gene therapy and exon-skipping, where one attempts either to repair genetic defects or help the body produce a shortened version of dystrophin.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 55 | - | - | ||
| 3 950 | - | - | ||
| 50 | - | - | ||
| 10 000 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt